arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

RELMADA THERAPEUTICS, INC.

RLMD
$4.93 ▼ -0.45 (-8.36%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
58 Visible periods
24 Metrics
Peer-ranked Benchmarks
Price Chart
25
Health
Poor
Bearish
auto_awesome

Analytical Summary

RELMADA THERAPEUTICS, INC. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $426.9M
Dividend Yield
Revenue Growth None
Op. Margin None
ROIC -7.0%
FCF / Share $-0.17
Trailing P/E
Price / Book 2.4x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

58-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$634.00
↑ +58.5%
Net Income Profit after all expenses
$-19.05M
↓ -8.5%
Operating Margin Operating profit as % of sales
-479.4%
↓ -5643.6%
FCF / Share Free cash flow per share
$-0.17
↑ +70.7%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
13
Cash Quality
54

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 15 years · 58 quarters